Oaktree Acquisition III Life Sciences, a blank check company formed by Oaktree Capital targeting healthcare businesses, raised $175 million by offering 17.5 million units at $10. Each unit consists of one share of common stock and one-fifth of a warrant, exercisable at $11.50.
The company is led by Chairman John Frank, Vice Chairman of Oaktree Capital, and CEO Zaid Pardesi, Managing Director of Oaktree's private debt strategy. The executives led previous Oaktree-founded SPACs, including Oaktree Acquisition, which completed a business combination with Hims & Hers Health (NYSE: HIMS; +114% from $10 offer price) in 2021; Oaktree Acquisition II, which completed a business combination with Alvotech (Nasdaq: ALVO; +29%) in 2022; and Oaktree Acquisition III, which withdrew its proposed offering in 2023. The company plans to target healthcare or healthcare-related industries.
Oaktree Acquisition III Life Sciences plans to list on the Nasdaq under the symbol OACCU. Jefferies, Citi, and UBS Investment Bank acted as joint bookrunners on the deal.
SPAC Oaktree Acquisition III Life Sciences prices $175 million IPO, formed by Oaktree Capital
October 24, 2024
